Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:27:13.358Z.
Calculation as of: 2026-10-06T14:27:13.358Z.
Quote observation: 2026-10-06T14:23:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
PEG RATIO
N/A
Market Cap
$110.73M
PEG Ratio
N/A
TTM Avg
8.77
3Y Avg
19.79
5Y Avg
19.79
Market Cap
$109.20M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $112.52M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $109.24M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | N/A | 8.77 | 19.79 | 19.79 |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.91M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.79M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $109.21M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
